Trinity Biotech (TRIB) Operating Expenses (2009 - 2024)

Trinity Biotech has disclosed Operating Expenses across 16 years of filings, most recently posting -$9.8 million for Q4 2024.

• Operating Expenses for Q4 2024 came in at -$9.8 million, down 21.95% year-over-year; the trailing twelve-month figure through Dec 2025 was -$17.4 million (up 47.98% YoY), and the FY2025 annual result was $28.3 million, down 16.06% from the prior year.
• Operating Expenses came in at -$9.8 million for Q4 2024 at Trinity Biotech, down from -$7.5 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of -$6.2 million in Q2 2020 to a low of -$10.8 million in Q4 2022.
• The 5-year median for Operating Expenses is -$7.5 million (2020), against an average of -$7.9 million.
• Across the five-year window, Operating Expenses slumped 66.22% in 2022 and gained 25.69% in 2023, its largest moves.
• Trinity Biotech's Operating Expenses stood at -$8.2 million in 2020, then advanced by 20.03% to -$6.5 million in 2021, then sank by 66.22% to -$10.8 million in 2022, then climbed by 25.69% to -$8.1 million in 2023, then retreated by 21.95% to -$9.8 million in 2024.
• The last three Operating Expenses figures came in at -$9.8 million (Q4 2024), -$7.5 million (Q3 2024), and -$7.4 million (Q2 2024), per Business Quant data.